VRDN
Viridian Therapeutics, Inc.
There isn't enough reported data to score VRDN yet.
VRDN Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Unavailable |
VRDN's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
VRDN PE Valuation
VRDN has no meaningful PE right now: it lost money over the past year.
VRDN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect VRDN's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
VRDN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$3.86 | +$0.44 |
| Q2 2025 | -$4.65 | -$0.41 |
| Q1 2025 | -$4.44 | +$0.05 |
| Q4 2024 | -$4.16 | +$1.15 |
| Q3 2024 | -$4.30 | +$0.82 |
| Q2 2024 | -$4.24 | +$0.65 |
| Q1 2024 | -$4.49 | +$0.19 |
| Q4 2023 | -$5.31 | -$1.26 |
VRDN is still losing money, but far less than before: $3.86 per share over the past year, against $31.75 at its worst in mid-2021.
VRDN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $25.8M | -64% |
| Q2 2026 | $284K | +279% |
| Q1 2026 | $141K | +96% |
| Q4 2025 | $132K | +83% |
| Q3 2025 | $70.6M | +81958% |
| Q2 2025 | $75K | +4.2% |
| Q1 2025 | $72K | 0% |
| Q4 2024 | $72K | 0% |
VRDN's revenue has slid since its 2025 peak: $26M last quarter, down 64% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -402% | -345 points |
| Q2 2026 | -44461% | +97895 points |
| Q1 2026 | -82389% | +47980 points |
| Q4 2025 | -92992% | +28497 points |
| Q3 2025 | -57% | +97013 points |
| Q2 2025 | -142356% | -42096 points |
| Q1 2025 | -130369% | -52735 points |
| Q4 2024 | -121489% | -22214 points |
VRDN's operating margin was −402% last quarter, down 345 points from the same quarter a year ago, near the top of its range since 2019.
VRDN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$93.1M | -$8.4M |
| Q2 2026 | -$106.6M | -$31.2M |
| Q1 2026 | -$119.7M | -$26.9M |
| Q4 2025 | -$24M | +$49.5M |
| Q3 2025 | -$84.7M | -$16.7M |
| Q2 2025 | -$75.4M | -$29.3M |
| Q1 2025 | -$92.7M | -$47.5M |
| Q4 2024 | -$73.4M | -$35.4M |
VRDN has burned cash in almost every quarter: −$343M over the past year, against −$326M the year before.
VRDN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +266K shares |
| 1 year | +19% | +18.1M shares |
| 3 years | +163% | +70.3M shares |
| 5 years | +2953% | +110M shares |
VRDN has 114M diluted shares, up 19% from a year ago.
VRDN Net Leverage
VRDN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
VRDN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 69.2 | Neutral |
| Stochastic | 91.0 | Overbought |
VRDN's weekly RSI is 69 (neutral) and its Stochastic is 91 (overbought).
VRDN PE vs Healthcare Sector
VRDN has no meaningful PE right now: it lost money over the past year.
VRDN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $23.0 | 33% above |
| 20 week MA | $21.9 | 39% above |
| 50 week MA | $23.3 | 31% above |
| 100 week MA | $20.7 | 48% above |
| 200 week MA | $20.4 | 49% above |
VRDN is in an uptrend: it's above all five of its weekly moving averages, and 49% above its 200-week average.
VRDN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $7.62 | $17.6 | +131% |
| 2021 | $17.6 | $21.5 | +22% |
| 2022 | $21.5 | $29.6 | +38% |
| 2023 | $29.6 | $21.8 | -26% |
| 2024 | $21.8 | $19.5 | -11% |
| 2025 | $19.5 | $31.9 | +64% |
| 2026 YTD | $31.9 | $30.5 | -4.4% |
VRDN has finished higher in four of the last six years, two of them by more than 50%. It's down 4.4% so far in 2026.